izindlela ezintsha zokwelapha umdlavuza wamaphaphu wamangqamuzana amancane

Umdlavuza wamaphaphu ongewona omncane (NSCLC) uyimbangela ehamba phambili yokufa okuhlobene nomdlavuza emhlabeni jikelele. Ngenhlanhla, intuthuko ebalulekile ezinkethweni zokwelapha iyavela, inikeza ithemba elisha lemiphumela ethuthukisiwe kanye nezinga lempilo. Lesi sihloko sihlola okwakamuva izindlela ezintsha zokwelapha umdlavuza wamaphaphu wamangqamuzana amancane, okuhlanganisa izindlela zokwelapha ezihlosiwe, ama-immunotherapies, inhlanganisela yokwelapha ngamakhemikhali, nezivivinyo zomtholampilo ezintsha.Ukuqonda Umdlavuza Ongewona Owomncane Wengqamuzana Wamaphaphu (NSCLC)Umdlavuza wamaphaphu ongewona omncane (NSCLC) uwuhlobo oluvame kakhulu lomdlavuza wamaphaphu, olubalelwa cishe ku-80-85% wazo zonke izifo zokuxilonga umdlavuza wamaphaphu. Ihlanganisa izinhlobo ezimbalwa ezincane, okuhlanganisa i-adenocarcinoma, i-squamous cell carcinoma, kanye ne-cell carcinoma enkulu. Isigaba se-NSCLC ekuxilongeni sithinta kakhulu izinketho zokwelapha kanye nokubikezelwa. I-NSCLC yesigaba sangaphambi kwesikhathi ingase yelashwe ngokuhlinzwa, kuyilapho izigaba ezithuthukile ngokuvamile zidinga inhlanganisela yezindlela zokwelapha.Izindlela zokwelapha ezihlosiwe ze-NSCLCImithi yokwelapha ehlosiwe yizidakamizwa eziqondise ngokuqondile amaprotheni athile noma izakhi zofuzo ezifaka isandla ekukhuleni kwamangqamuzana omdlavuza futhi asinde. Lezi zindlela zokwelapha zivame ukusebenza kahle futhi zinemiphumela emibi embalwa kune-chemotherapy yendabuko. Okuhlosiwe okujwayelekile ku-NSCLC kufaka phakathi i-EGFR, ALK, ROS1, BRAF, kanye ne-MET.EGFR InhibitorsI-Epidermal growth factor receptor (EGFR) iphrotheni esiza amaseli ukuthi akhule futhi ahlukanise. Amanye amathumba e-NSCLC anokuguqulwa kwezakhi zofuzo ze-EGFR, okuholela ekukhuleni kwamaseli okungalawuleki. I-EGFR inhibitors, njenge-gefitinib, i-erlotinib, i-afatinib, ne-osimertinib, ivimbela umsebenzi we-EGFR, inciphisa noma imise ukukhula kwesimila.Izinzuzo: Ngokuvamile kusebenza ezigulini ezinokuguqulwa kwe-EGFR, okuholela ekusindeni okuthuthukisiwe kanye nekhwalithi yokuphila.Imiphumela Emibi: Ukuqubuka kwesikhumba, isifo sohudo, ukukhathala.I-Osimertinib ivamise ukuba yindlela yokwelapha yokuqala ekhethwayo ye-EGFR-mutated NSCLC, ebonisa ukusebenza kahle okuphakeme uma kuqhathaniswa nesizukulwane sangaphambili se-EGFR inhibitors. Ungafunda kabanzi mayelana ne-EGFR inhibitors kusuka ku- Iwebhusayithi ye-American Cancer Society.ALK InhibitorsI-Anaplastic lymphoma kinase (ALK) enye iphrotheni engashintshwa ku-NSCLC. I-ALK inhibitors, njenge-crizotinib, i-ceritinib, i-alectinib, i-brigatinib, ne-lorlatinib, iqondise iphrotheni ye-ALK, ivimbela umsebenzi wayo futhi ivimbele ukukhula kwesimila.Izinzuzo: Isebenza kahle ezigulini ezinokuhlelwa kabusha kwe-ALK, okuholela ekusindeni okuthuthukisiwe nokunciphisa ukuqhubeka kwesifo.Imiphumela Emibi: Izinguquko zombono, isicanucanu, ukuhlanza, isifo sohudo, ukukhathala.I-Alectinib ne-Lorlatinib zivame ukukhetha ukwelashwa komugqa wokuqala ngenxa yokusebenza kahle kwazo okuthuthukisiwe kanye nekhono lokungena emgodleni wegazi nobuchopho, okubalulekile ezigulini ezinemetastase yobuchopho. Ucwaningo lweCancer UK inikeza ulwazi olwengeziwe.I-ROS1 InhibitorsROS1 iyi-receptor tyrosine kinase okuthi, uma ihlanganiswe nolunye ufuzo, ingaqhuba ukukhula komdlavuza. I-ROS1 inhibitor, njenge-crizotinib ne-entrectinib, isetshenziselwa ukwelapha i-NSCLC nge-ROS1 fusions.Izinzuzo: Ukuncipha kwesimila esibalulekile kanye nokuhlala isikhathi eside ezigulini ezine-ROS1-positive NSCLC.Imiphumela Emibi: Ngokufana ne-ALK inhibitors.I-Entrectinib ibonise isithembiso ngenxa yekhono layo lokuwela umgoqo wegazi nobuchopho, okwenza iphumelele ekwelapheni ama-metastases ebuchosheni. Hlola Iwebhusayithi ye-European Medicines Agency ukuze uthole ulwazi oluningiliziwe.I-Immunotherapy ye-NSCLCImmunotherapy ihlanganisa amandla amasosha omzimba okulwa nomdlavuza. Ama-immune checkpoint inhibitors awuhlobo lwe-immunotherapy oluvimba amaprotheni avimbela amasosha omzimba ekuhlaseleni amangqamuzana omdlavuza.PD-1/PD-L1 InhibitorsProgrammed cell death protein 1 (PD-1) kanye ne-programmed death-ligand 1 (PD-L1) angamaprotheni asiza amangqamuzana omdlavuza ukuba abaleke amasosha omzimba. I-PD-1/PD-L1 inhibitors, njenge-pembrolizumab, i-nivolumab, i-atezolizumab, ne-durvalumab, ivimba la maprotheni, okuvumela amasosha omzimba ukuba abone futhi ahlasele amangqamuzana omdlavuza.Izinzuzo: Izimpendulo ezihlala isikhathi eside kanye nokusinda okuthuthukisiwe kusethi yeziguli ezine-NSCLC.Imiphumela Emibi: Imiphumela engathandeki ehlobene namasosha omzimba, njenge-pneumonitis, i-colitis, ne-hepatitis.I-Pembrolizumab ivame ukusetshenziswa njengokwelashwa komugqa wokuqala ezigulini ze-NSCLC ezinenkulumo ephezulu ye-PD-L1. Olunye ulwazi lungatholakala ku- Iwebhusayithi ye-FDA.I-CTLA-4 InhibitorsI-protein 4 ehambisana ne-T-lymphocyte 4 (CTLA-4) ingenye iphrotheni engacindezela amasosha omzimba. I-Ipilimumab iyi-CTLA-4 inhibitor engasetshenziswa ngokuhambisana ne-PD-1 inhibitors ukuze kuthuthukiswe ukusabela komzimba kumaseli omdlavuza.Izinzuzo: Ingase ithuthukise ukusinda uma ihlanganiswa ne-PD-1 inhibitors.Imiphumela Emibi: Imiphumela emibi ebaluleke kakhulu ehlobene nokuzivikela komzimba uma iqhathaniswa ne-PD-1 inhibitors iyodwa.Izinhlanganisela Zokwelapha Ngamakhemikhali Nakuba izindlela zokwelapha ezihlosiwe kanye ne-immunotherapies kuye kwashintsha ukwelashwa kwe-NSCLC, ukwelapha ngamakhemikhali kuseyindlela ebalulekile, ikakhulukazi uma kuhlanganiswe nezinye izindlela zokwelapha. Izindlela zokwelapha ezintsha ezingezona ezincane zomdlavuza wamaphaphu ngokuvamile kuhlanganisa ukuhlanganisa ukwelapha ngamakhemikhali nokwelashwa kwamasosha omzimba noma imithi yokwelapha ehlosiwe ukuze ithuthukise ukusebenza kwayo. izindlela ezintsha zokwelapha umdlavuza wamaphaphu wamangqamuzana amancane. Le ndlela ithuthukisa amandla e-chemotherapy ukulimaza amangqamuzana omdlavuza futhi akhulule ama-antigen, okuwenza abe sengozini yokuhlaselwa amasosha omzimba. Ukwengezwa kwe-immunotherapy kungase kukhulise impendulo yokuzivikela komzimba, okuholela emiphumeleni ethuthukisiwe.Izinzuzo: Amazinga athuthukisiwe okusinda nokusabela uma kuqhathaniswa ne-chemotherapy kuphela.Imiphumela Emibi: Ukwenyuka kwengozi yakho kokubili ukwelapha ngamakhemikhali kanye nemiphumela engemihle ehlobene nokuzivikela komzimba.Inhlanganisela Yokwelapha Okuhlosiwe kanye Nemithi YamakhemikhaliEzimweni ezithile, ukuhlanganisa ukwelashwa okuhlosiwe ne-chemotherapy kungase kube yinzuzo, ikakhulukazi ezigulini eziye zaqala ukumelana nokwelashwa okuhlosiwe kuphela. Le ndlela ingasiza ukunqoba izindlela zokungazweli futhi ithuthukise imiphumela yokwelashwa.Izinzuzo: Ingase ibuyisele ukuzwela ekwelapheni okuqondisiwe futhi ithuthukise ukusinda.Imiphumela Emibi: Ukwanda kwengozi yemiphumela engemihle kuzo zombili izindlela zokwelapha.Izilingo Zomtholampilo: Ikusasa Lokwelashwa kwe-NSCLCIzinhlolo zomtholampilo izifundo zocwaningo ezihlolayo. izindlela ezintsha zokwelapha umdlavuza wamaphaphu wamangqamuzana amancane namasu. Ukubamba iqhaza ocwaningweni lomtholampilo kunganikeza ukufinyelela kumakhambi asezingeni eliphezulu angakatholakali kabanzi. I-Shandong Baofa Cancer Research Institute izibophezele ekuthuthukiseni ucwaningo lomdlavuza futhi ihlinzeka ngezinsizakalo futhi ibamba iqhaza ezivivinyweni zokwelashwa ezihlinzeka ngokufinyelela ekwelashweni kwesimanje okungakatholakali kabanzi. Funda kabanzi mayelana nezivivinyo zomtholampilo e-Shandong Baofa Cancer Research Institute.Izindlela Zokwelapha Ezisafufusa Ezivivinyweni ZomtholampiloZiningana ezithembisayo izindlela ezintsha zokwelapha umdlavuza wamaphaphu wamangqamuzana amancane okwamanje ziyahlolwa ezivivinyweni zomtholampilo, okuhlanganisa:Ama-antibody-drug conjugates (ADCs): Le mithi iletha i-chemotherapy ngqo kumaseli omdlavuza, inciphisa ukulimala kwamaseli anempilo.Ama-antibodies ama-Bispecific: Lawa ma-antibodies abopha womabili amaseli omdlavuza namaseli omzimba, awahlanganise ukuze athuthukise ukusabela komzimba.Ukwelashwa ngamaselula (isb., ukwelashwa kweseli ye-CAR-T): Lezi zindlela zokwelapha zihlanganisa ukuguqula amangqamuzana omzimba ukuze aqondise futhi abhubhise amangqamuzana omdlavuza.Ukuphila ne-NSCLC: Izinsiza NokwesekwaUkuphila ne-NSCLC kungaba inselele, kodwa izinsiza eziningi kanye namaqembu okusekela ayatholakala ukuze asize iziguli nemindeni yazo zibhekane nesifo. Cabangela ukuhlola izinsiza ezivela ezinhlanganweni ezifana ne I-American Lung Association noma i LUNGevity Foundation.Umshwana wokuzihlangula: Lesi sihloko senzelwe izinjongo zokwaziswa kuphela futhi akufanele sithathwe njengeseluleko sezokwelapha. Sicela uxhumane nomhlinzeki wakho wokunakekelwa kwezempilo ukuze uthole izincomo zokwelashwa eziqondene nawe.